Treatment of methicillin-resistant staphylococcal infections: Better use of available drugs or introduction of new antimicrobial agents?;Traitement des infections à staphylocoques résistants à la méticilline: Optimisation des traitements disponibles ou utilisation de nouvelles molécules?

Reanimation Urgences

Volumn 10, Issue 3, 2001, Pages 329-335

  Gibert, C ^a   Trouillet, J L ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

Antimicrobial agents; Methicillin resistance; Staphylococcal infection; Vancomycin

Indexed keywords

VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG SENSITIVITY; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; PENICILLIN RESISTANCE; REVIEW; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; STRAIN DIFFERENCE; TREATMENT FAILURE;

EID: 0034987286     PISSN: 11646756     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Methicillin resistance in staphylococci: Molecular and biochemical basis and clinical implications
2. Surveillance des staphylococoques dorés et klebsielles multirésistants à l'Assistance Publique Hôpitaux de Paris (1993-1996)
3. Methicillin resistant Staphylococcus aureus in French hospitals: A 2-month survey in 43 hospitals
4. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting
5. Pathogenic significance of methicillin resistance for patients with Staphylococcus aureus bacteremia
6. Bacteremic pneumonia due to Staphylococcus aureus: A compa- rison of disease caused by methicillin-resistant and methicillin-susceptible organisms
7. Rapid extraction from and direct identification in clinical samples of methicillin-resistant staphylococci using the PCR
8. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital
9. Outbreak of methicillin-resistant Staphylococcus aureus with reduced susceptibility to glycopeptides in a Parisian hospital
10. Le point sur la situation épidémiologique actuelle de Staphylococcus aureus de sensibilité diminuée aux glycopeptides (Vancomycine et teicoplanine) en France
11. Glycopeptides
12. Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections
13. Urea kinetics and dialysis treatment time predict vancomycin elimination during high-flux hemodialysis
14. Use of vancomycin in high-flux hemodialysis: Experience with 130 courses of therapy
15. Vancomycin clearance during continuous venovenous haemodiafiltration in critically ill patients
16. Penetration of teicoplanine into heart valves and subcutaneous and muscle tissues of patients undergoing open-heart surgery
17. 14 teicoplanin in experimental Staphylococcus diffusion pattern aureus infection of joint prostheses
18. Decreased teicoplanin susceptibility of methicillin-resistant strains of Staphylococcus aureus
19. Teicoplanin therapy for Staphylococcus aureus septicemia: Relationship between pre-dose serum concentrations and outcome
20. Single dose phamacokinetics of teicoplanin during hemodialysis therapy using high-flux polysulfone membranes
21. Importance of penicillinase production for activity of penicillin alone or in combination with sulbactam in experimental endocarditis due to methicillin-resistant Staphylococcus aureus
22. Antibiotic treatment of experimental endocarditis due to methicillin-resistant Staphylococcus epidermidis
23. The impact of penicillinase on cefamandole treatment and prophylaxis of experimental endocarditis due to methicillin resistant Staphylococcus aureus
24. Ochsner PE for the foreign-body infection (FBI) study group. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: A randomized controlled trial
25. Pharmacodynamics of levofloxacin. A new paradigm for early clinical trials
26. Emergence of vancomycin resistance in Staphylococcus aureus
27. Reconsideration of rifampin: A unique drug for a unique infection
28. Oral rifampin plus azithromycin or clarithromycin to treat osteomyelitis in rabbits
29. Teicoplanin lone or combined with rifampin compared with vancomycin for prophylaxis and treatment of experimental foreign body infection by methicillin-resistant Staphylococcus aureus
30. Oral antibiotic treatment of right-sided staphylococcal endocarditis in infection drug users: Prospective randomized comparison with parenteral therapy
31. Ampicillin, Sulbactam, and Rifampin combination treatment of experimental methicillin-resistant Staphylococcus aureus endocarditis in rabbits
32. Characterization of gentamicin-susceptible strains of methicillin-resistant Staphylococcus aureus involved in nosocomial spread
33. In vitro and in vivo antibacterial activity of quinupristin-dalfopristin
34. Nationwide German multicenter study on prevalence of antibiotic resistance in staphylococcal bloodstream isolates and comparative in vitro activities of quinupristin-dalfopristin
35. In vitro activities of daptomycin, vancomycin, linezolid and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin-intemediate and resistant strains
36. Current and future management of infections due to methicillin-resistant staphylococci infections: The role of quinupristin-dalfopristin
37. Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin-dalfopristin versus vancomycin
38. Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy
39. Safety and tolerability of quinupristin-dalfopristin: Administration guidelines
40. Pharmacokinetics of quinupristin-dalfopristin in continuous ambulatory peritoneal dialysis patients
41. Quinupristin-dalfopristin combined with ß-lactams for treatment of experimental endocarditis due to Staphylococcus aureus constitutively resistant to macrolide-lincosamide- streptogramin B antibiotics
42. Emerging therapies for serious gram-positive bacteriae infections: A focus on linozolid
43. Linezolid therapy of Staphylococcus aureus experimental osteomyelitis
44. Activities of LY333328 and vancomycin administrated alone or in combination with gentamicin against three strains of vancomycin intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model
45. In vitro activities of daptomycin, arbekacin, vancomycin, and gentamicin alone and/or in combination against glycopeptide intermediate-resistant Staphylococcus aureus in an infection model